What is Crispr Therapeutics AG (CRSP) stock price today?

Crispr Therapeutics AG (CRSP) currently trades at $50.71 per share. The stock has a market capitalization of $4.70B and a P/E ratio of —x.

Is CRSP stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Crispr Therapeutics AG has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is 3.04.

What is Crispr Therapeutics AG's revenue and earnings?

Crispr Therapeutics AG has trailing twelve-month (TTM) revenue of $3.51M with profit margins of 0.00%. Earnings per share (EPS) is $-6.47.

Is Crispr Therapeutics AG financially healthy?

Crispr Therapeutics AG's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of 3.04 places it in the safe zone.

CRSP

Crispr Therapeutics AG

NASDAQ: CRSP · HEALTHCARE · BIOTECHNOLOGY

$50.71

-2.59% today

Updated 2026-04-29

Market cap

$4.70B

P/E ratio

—

P/S ratio

1,340.31x

EPS (TTM)

$-6.47

Dividend yield

—

52W range

$33 – $78

Volume

2.0M

Market cap

$4.70B

P/E ratio

—

P/S ratio

1,340.31x

EPS (TTM)

$-6.47

Dividend yield

—

52W range

$33 – $78

Volume

2.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

7.3

Quality

B+

2.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

3.0

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

$83.35

+64.37%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

5 Strong Buy12 Buy9 Hold1 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 3.04 — safe zone

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-93.07M

- Revenue declining -97.60% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$436000.00	$370.00M	$35.00M	$3.51M	$3.51M
Net income	$-650.17M	$-153.61M	$-366.25M	$-581.60M	$-130.61M
EPS	—	—	—	—	$-6.47
Free cash flow	$-532.93M	$-269.85M	$-144.68M	$-345.93M	$-93.07M
Profit margin	-149,122.71%	-41.52%	-1,046.43%	-16,569.77%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CRSP	$4.70B	27	5.3	2.5	5.0	7.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Crispr Therapeutics AG trades at $50.71. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 3.04, it sits in the safe zone. TTM revenue stands at $3.51M.

Frequently asked questions

What is Crispr Therapeutics AG's stock price?

Crispr Therapeutics AG (CRSP) trades at $50.71.

Is Crispr Therapeutics AG overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of Crispr Therapeutics AG (CRSP)?

The analyst target price is $83.35, representing +64.4% upside from the current price of $50.71.

What is Crispr Therapeutics AG's revenue?

TTM revenue is $3.51M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

3.04 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1,340.31x

ROE-30.20%

Beta1.79

50D MA$52.58

200D MA$56.57

Shares out0.10B

Float0.10B

Short ratio—

Avg volume2.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CRSP vs LLY →CRSP vs JNJ →CRSP vs ABBV →Stock screener →